Reviva may be most undervalued in neurology, says H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju says recent takeovers in the neurology arena underscores the opportunity in shares of Reviva Pharmaceuticals. (RVPH). The recent buyouts of Karuna Therapeutics (KRTX) and Cerevel Therapeutics (CERE) “serve to emphasize the clear opportunity for investors in Reviva shares, particularly since Reviva trades at a market cap of $130M,” the analyst tells investors in a research note. The firm reminds investors that Reviva has a “risk-mitigated” lead asset, brilaroxazine, in late-stage development for treatment of schizophrenia “that boasts a highly favorable efficacy and safety profile.” Wainwright believes Reviva may be the most undervalued and underrated publicly traded company in the neurology arena today. It reiterates a Buy rating on the shares with a $20 price target.